Spring Bank Pharmaceuticals (NASDAQ:SBPH) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research note issued on Friday. The firm currently has a $12.00 price target on the stock. Zacks Investment Research‘s price target suggests a potential upside of 10.60% from the company’s previous close.

According to Zacks, “Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of therapeutics using its proprietary small molecule nucleic acid hybrid chemistry platform. The company is developing SB 9200, for the treatment of viral diseases, including hepatitis B virus. Spring Bank Pharmaceuticals, Inc. is based in Hopkinton, United States. “

SBPH has been the subject of several other reports. Cantor Fitzgerald set a $34.00 target price on shares of Spring Bank Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, December 7th. Chardan Capital set a $45.00 target price on shares of Spring Bank Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, November 30th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Spring Bank Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $28.80.

SBPH stock opened at $10.85 on Friday. Spring Bank Pharmaceuticals has a 12 month low of $8.14 and a 12 month high of $15.73. The company has a market cap of $178.34 million, a P/E ratio of -5.80 and a beta of 0.80.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last released its earnings results on Monday, March 11th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.17. Equities analysts predict that Spring Bank Pharmaceuticals will post -2.17 EPS for the current year.

Several large investors have recently modified their holdings of SBPH. Rhumbline Advisers purchased a new stake in shares of Spring Bank Pharmaceuticals in the 3rd quarter valued at approximately $122,000. Blair William & Co. IL purchased a new stake in shares of Spring Bank Pharmaceuticals in the 3rd quarter valued at approximately $123,000. JPMorgan Chase & Co. lifted its position in shares of Spring Bank Pharmaceuticals by 464.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 12,712 shares of the company’s stock valued at $153,000 after acquiring an additional 10,458 shares in the last quarter. Pegasus Asset Management Inc. purchased a new stake in shares of Spring Bank Pharmaceuticals in the 4th quarter valued at approximately $195,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Spring Bank Pharmaceuticals in the 4th quarter valued at approximately $206,000. Institutional investors and hedge funds own 43.18% of the company’s stock.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).

Featured Article: Why is the ex-dividend date different from the record date?

Get a free copy of the Zacks research report on Spring Bank Pharmaceuticals (SBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.